Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New insights into insect antimicrobials point the way to novel antibiotics

09.08.2002


The emergence of antibiotic-resistant strains of bacteria has become a serious public-health concern, and, accordingly, scientists are investigating new classes of antimicrobials for their efficacy against disease-causing bacteria. One developing area of study involves antimicrobial peptides derived from insects. Recent studies have identified the protein target in bacteria of these antimicrobial peptides and suggested that the peptides are not toxic to mammalian cells including those of humans, raising the possibility that they could someday be used to develop new antibiotic drugs.

Now, in a new study of an insect-derived antimicrobial peptide called pyrrhocoricin, scientists at The Wistar Institute have identified which segments of the peptide are necessary for the killing of bacteria and which segments are involved in bacterial and mammalian cell entry. The Wistar scientists further confirmed that this antimicrobial peptide must bind to the previously identified intracellular bacterial protein target in order to kill bacteria. The research team also identified a possible binding site for the antimicrobial peptide on the target bacterial protein for the first time.

Because the stretches of the peptide that are responsible for cell entry are separate from the segments responsible for bacteria killing, the research team says that it might be possible to use an altered version of the peptide as a delivery vehicle for a variety of drugs into human cells, rather than solely as an antimicrobial. The results are published online today in the European Journal of Biochemistry.



"This study lays the groundwork for the design of a novel family of antimicrobials," says Laszlo Otvos Jr., Ph.D., associate professor at The Wistar Institute and senior author of the study. "It also suggests that these peptides could be used as a universal drug delivery vehicle, whether for new drugs or to improve the delivery of existing peptide-based drugs."

The antimicrobial peptide kills bacteria by binding to a protein target called DnaK. DnaK is a special type of protein called a heat-shock protein, responsible for correcting misshapen proteins. When the antimicrobial peptide binds to DnaK, it prevents DnaK from doing its protein-repair work, killing the bacteria.The Wistar research team studied the binding of engineered analogs of pyrrhocoricin to a series of bacterial strains. As they anticipated based on their previous investigations, they found a complete correlation between the peptide binding to a small fragment of bacterial DnaK and bacteria killing. The researchers also confirmed that the peptide does not bind to the mouse or human protein equivalents to DnaK, further suggesting that the peptide would not be toxic to mammals.

The investigators identified a possible binding surface for the antimicrobial peptide on an E. coli DnaK fragment. Knowledge of this binding site could lead to the development of new drugs tailored to combat E. coli. It may also be possible to develop drugs that would kill bacteria that are unresponsive to native pyrrhocoricin, but for which the DnaK structure is known.

In related ongoing studies, Otvos and his team have shown that analogs of pyrrhocoricin are able to kill clinical strains of resistant bacteria that cause urinary, gastrointestinal and respiratory-tract infections. In a mouse H. influenzae lung infection model, the researchers have shown that a pyrrhocoricin analog can dramatically reduce bacterial counts in the lungs and be administered in a non-invasive way. These studies are demonstrating that engineered antibacterial peptides can be used in a clinical setting against bacteria with resistance to existing antibiotics.


In addition to senior author Otvos, the lead author of the study is Goran Kragol, Ph.D., and co-authors are Michael A. Chattergoon, B.S., Mare Cudic, Ph.D., Barry A. Condie, B.S., and associate professor Luis J. Montaner, D.V.M., D.Phil., all of The Wistar Institute. Additional co-authors are Ralf Hoffmann, Ph.D., of Heinrich-Heine-Universität, Sandor Lovas, Ph.D., of Creighton University, Philippe Bulet, Ph.D., of Institut de Biologie Moleculaire et Cellulaire, and K. Johan Rosengren, Ph.D., of the University of Queensland.

The Wistar Institute is an independent nonprofit biomedical research institution dedicated to discovering the causes and cures for major diseases, including cancer, cardiovascular disease, autoimmune disorders, and infectious diseases. Founded in 1892 as the first institution of its kind in the nation, The Wistar Institute today is a National Cancer Institute-designated Cancer Cente- one of only eight focused on basic research. Discoveries at Wistar have led to the development of vaccines for such diseases as rabies and rubella, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.

Marion Wyce | EurekAlert!
Further information:
http://www.wistar.upenn.edu),

More articles from Health and Medicine:

nachricht Light beam replaces blood test during heart surgery
28.02.2017 | University of Central Florida

nachricht Cells adapt ultra-rapidly to zero gravity
28.02.2017 | Universität Zürich

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Existence of a new quasiparticle demonstrated

28.02.2017 | Materials Sciences

Sustainable ceramics without a kiln

28.02.2017 | Materials Sciences

Biofuel produced by microalgae

28.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>